Implantica Hosts Capital Markets Day to Highlight U.S. Strategy for RefluxStop®

VADUZ, Liechtenstein, Sept. 8, 2026 /CourierPR/ -- Implantica AG, a medtech company focused on advanced implantable technologies, is set to host its Capital Markets Day on September 9, 2026, in Stockholm. The event, which runs from 14:00 to 16:30 Central European Summer Time (CEST), aims to provide investors and the media with a comprehensive overview of the company’s strategic plans post-FDA approval of its RefluxStop® device. The focus will be on the company’s U.S. market launch strategy and the significant growth opportunities in a market where an estimated 78 million people in the United States suffer from acid reflux.

The Capital Markets Day will bring together Implantica’s management team, surgeons who have used the RefluxStop® device, and patients to share insights into the product. The event will cover both clinical and patient perspectives, with the management team presenting the company’s strategy for the U.S. rollout and future developments. Attendees will have the opportunity to engage with the company’s leadership and gain a deeper understanding of the potential impact of RefluxStop® on the standard of care for gastroesophageal reflux disease (GERD).

RefluxStop® is an FDA-approved and CE-marked implant designed to address the root cause of acid reflux without the side effects associated with conventional surgical procedures. The device aims to restore and maintain the lower esophageal sphincter in its natural anatomical position, thereby reducing or eliminating acid and non-acid reflux. Clinical outcomes from a multitude of centers support the success of the device, with long-term 5-year data published in peer-reviewed scientific journals.

Implantica’s management team will outline the company’s plans to capitalize on the significant growth opportunity in the U.S. market. The strategy includes leveraging the strong long-term clinical outcomes of RefluxStop® to attract new patients and surgeons. The event will also highlight the company’s broader product pipeline, which includes an eHealth platform for remote monitoring and control of implants and a wireless energizing platform for powering implantable devices.

Implantica AG is listed on the Nasdaq First North Premier Growth Market in Stockholm and is committed to improving patient outcomes and quality of life through advanced implantable technologies. The company’s listing on this market underscores its growth potential and financial transparency. Attendees will be able to join the event via live webcast, with the link provided on the company’s website.

By hosting this Capital Markets Day, Implantica aims to strengthen its position in the medtech sector and provide stakeholders with a clear roadmap for the company’s future growth and success.